Sequana Medical Announces First Satellite Symposium and Key Data from its European Randomized Controlled Trial of the alfapump® System to be Presented at The International Liver Congress™ (ILC) 2016 in Barcelona, Spain, on 16 April 2016

Apr 14, 2016, 01:00 ET from Sequana Medical AG

ZURICH, April 14, 2016 /PRNewswire/ --

Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative, implantable pump systems that manage fluid build-up occurring in patients with liver disease, certain cancers and congestive heart failure, announced today that the company will host its first satellite symposium, entitled, "Therapeutic Advances in Refractory Ascites," at The International Liver Congress™ (ILC) 2016, the 51st Annual Meeting of the European Association for the Study of the Liver (EASL), being held at the Fira Barcelona Gran Via, Barcelona, Spain from 13-17 April 2016. Additionally, data from the company's 60-patient, European Randomized Controlled Trial of the alfapump® System will be presented in a scientific session by Prof. Rajiv Jalan, Ph.D., of the Royal Free Hospital, London. Sequana Medical is exhibiting at booth #2000N in Hall 8 throughout the Congress.

"As a Silver Sponsor at this year's ILC, we are pleased, together with our clinical investigators, to have the opportunity to present important data comparing the alfapump System to current standard of care, while also expanding the discussion and understanding of ascites, its impact on patients with liver disease and the role that the alfapump System has been playing in this key target market," stated Noel L. Johnson, Ph.D., Chief Executive Officer of Sequana Medical.

Satellite Symposium
Date: Saturday, 16 April 2016
Time: 7:30am - 8:30am CET
Location: Hall 8.0 - Room C2
Participants: Prof. Rajiv Jalan, Ph.D. (Royal Free Hospital, London), PD Dr. Andrea De Gottardi, Ph.D. (Inselspital, Bern), Prof. Thomas Berg, M.D. (University Leipzig)

Oral Presentation
Title: alfapump® System Versus Large Volume Paracentesis in the Treatment of Refractory Ascites; Results from a Multicenter Randomized Controlled Study (RCT)
Abstract: GS18
Date: Saturday, 16 April 2016
Time: 8:30am - 10:30am CET
Location: Hall 6.0
Session: General session 3 and awards 2
Presenter: Prof. Rajiv Jalan, Ph.D., Royal Free Hospital, London

About Sequana Medical:  

Founded in 2006, Sequana Medical AG is a Swiss medical device company backed by NeoMed Management, VI Partners, Biomed Invest, Capricorn Venture Partners, Entrepreneurs Fund, Life Science Partners, Salus Partners and Quest for Growth, and is dedicated to improving patient lives through innovative technologies to manage fluid overload in patients suffering from liver disease, cancer and congestive heart failure. The company's first marketed product, the alfapump System, is being used to manage ascites in liver patients and is currently sold in 17 countries in Europe, the Middle East and South America. For more information, please visit http://www.sequanamedical.com.

Contact:
Sequana Medical
Neil Inhaber, MD
Chief Medical Officer
neil.inhaber@sequanamedical.com
Tel: + 1-408-202-6148

SOURCE Sequana Medical AG